NO20071714L - Fremgangsmateer for behandling av CD30 positive lymfomer - Google Patents

Fremgangsmateer for behandling av CD30 positive lymfomer

Info

Publication number
NO20071714L
NO20071714L NO20071714A NO20071714A NO20071714L NO 20071714 L NO20071714 L NO 20071714L NO 20071714 A NO20071714 A NO 20071714A NO 20071714 A NO20071714 A NO 20071714A NO 20071714 L NO20071714 L NO 20071714L
Authority
NO
Norway
Prior art keywords
treatment
procedures
positive lymphomas
lymphomas
positive
Prior art date
Application number
NO20071714A
Other languages
English (en)
Norwegian (no)
Inventor
Elke Pogge Von Strandmann
Andreas Engert
Peter Borchmann
Boris Boell
Original Assignee
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex Inc filed Critical Medarex Inc
Publication of NO20071714L publication Critical patent/NO20071714L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20071714A 2004-10-01 2007-03-30 Fremgangsmateer for behandling av CD30 positive lymfomer NO20071714L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61528404P 2004-10-01 2004-10-01
PCT/US2005/035477 WO2006039644A2 (en) 2004-10-01 2005-09-30 Methods of treating cd30 positive lymphomas

Publications (1)

Publication Number Publication Date
NO20071714L true NO20071714L (no) 2007-06-28

Family

ID=35929979

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071714A NO20071714L (no) 2004-10-01 2007-03-30 Fremgangsmateer for behandling av CD30 positive lymfomer

Country Status (13)

Country Link
US (1) US7790160B2 (https=)
EP (1) EP1802345A2 (https=)
JP (1) JP2008514730A (https=)
KR (1) KR20070083899A (https=)
CN (1) CN101056655A (https=)
AU (1) AU2005292227A1 (https=)
BR (1) BRPI0516727A (https=)
CA (1) CA2582016A1 (https=)
IL (1) IL182260A0 (https=)
MX (1) MX2007003533A (https=)
NO (1) NO20071714L (https=)
WO (1) WO2006039644A2 (https=)
ZA (1) ZA200703154B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1471938A4 (en) * 2002-01-09 2008-03-05 Medarex Inc HUMAN MONOCLONAL ANTIBODIES AGAINST CD30
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
WO2006039644A2 (en) 2004-10-01 2006-04-13 Medarex, Inc. Methods of treating cd30 positive lymphomas
WO2006089232A2 (en) 2005-02-18 2006-08-24 Medarex, Inc. Monoclonal antibodies against cd30 lacking fucosyl residues
WO2006116246A2 (en) * 2005-04-25 2006-11-02 Medarex, Inc. Method of treating cd30 positive lymphomas
ES2396569T3 (es) * 2006-01-17 2013-02-22 Medarex, Inc. Anticuerpos monoclonales contra CD30 que carecen de restos fucosilo y xilosilo
US7910108B2 (en) * 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
WO2008124197A1 (en) * 2007-04-10 2008-10-16 The Johns Hopkins University Imaging and therapy of virus-associated tumors
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
CN107898791A (zh) 2010-06-03 2018-04-13 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
EP3575794A1 (en) * 2012-02-10 2019-12-04 Seattle Genetics, Inc. Detection and treatment of cd30+ cancers
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
SG11201601763SA (en) 2013-09-20 2016-04-28 Bristol Myers Squibb Co Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
JP6508785B2 (ja) * 2013-10-25 2019-05-08 ファーマサイクリックス エルエルシー ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置
EP3076963A4 (en) * 2013-12-06 2017-09-13 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
CA2954694A1 (en) * 2014-07-11 2016-01-14 Expression Pathology, Inc. Srm/mrm assay for the tumor necrosis factor receptor superfamily member 8 (cd30) protein
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
MA45862A (fr) * 2016-08-04 2021-05-05 Millennium Pharm Inc Combinaison d'inhibiteurs du protéasome et d'anticorps anti-cd30
CN106854245A (zh) * 2016-12-28 2017-06-16 无锡傲锐东源生物科技有限公司 抗cd30蛋白单克隆抗体及其用途
EP3630179A2 (en) 2017-05-30 2020-04-08 Bristol-Myers Squibb Company Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
SMT202300418T1 (it) 2017-05-30 2024-01-10 Bristol Myers Squibb Co Trattamento di tumori positivi per lag-3
WO2019148410A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1 antibodies
WO2022087402A1 (en) 2020-10-23 2022-04-28 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
JP7652918B2 (ja) 2021-03-01 2025-03-27 ナントバイオ，インコーポレイテッド 抗ｃｄ３０モノクローナル抗体及びキメラ抗原受容体

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5165923A (en) 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease
AU6909191A (en) 1989-11-20 1991-06-13 Parker, David L. Improved cd-30 antibodies and fragments thereof
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
DE4200043A1 (de) 1991-11-11 1993-05-13 Stein Harald Prof Dr Lymphoides cd30-antigen (ki-1), dessen protein- und die zugehoerige nucleotidsequenz, seine herstellung sowie mittel zur diagnose und untersuchung von tumoren
DE69334070T2 (de) 1992-05-26 2007-01-04 Immunex Corp., Thousand Oaks Neue zytokine die cd30 binden
WO1994004189A1 (en) 1992-08-25 1994-03-03 Medac Gesellschaft Fur Klinische Spezialpräparate Mbh Antibody/radioisotope conjugate for tumor diagnosis and/or therapy
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
DE4337197C1 (de) 1993-10-30 1994-08-25 Biotest Pharma Gmbh Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
WO1996022384A1 (en) 1995-01-18 1996-07-25 Boehringer Mannheim Gmbh Anti-cd 30 antibodies preventing proteolytic cleavage and release of membrane-bound cd 30 antigen
DE19543039C1 (de) 1995-11-08 1996-11-21 Medac Klinische Spezialpraep Rekombinante Liganden für das menschliche Zellmembran-Antigen CD30
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
WO1999040187A1 (de) 1998-02-06 1999-08-12 Hinrich Abken Nukleinsäuren zur modulation zellulärer aktivierung
DE19937264A1 (de) 1999-08-06 2001-02-15 Deutsches Krebsforsch F¶v¶-Antikörper-Konstrukte
US6652854B2 (en) 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
WO2002017979A2 (en) 2000-08-29 2002-03-07 Noveon Ip Holdings Corp. Dehydrated hydrogels
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
HUP0600342A3 (en) * 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
EP1471938A4 (en) * 2002-01-09 2008-03-05 Medarex Inc HUMAN MONOCLONAL ANTIBODIES AGAINST CD30
EP1532175B1 (en) 2002-03-22 2012-10-17 Aprogen, Inc. Humanized antibody and process for preparing the same
FR2844513B1 (fr) 2002-09-13 2007-08-03 Lab Francais Du Fractionnement Anticorps pour adcc et induisant la production de cytokines.
WO2006039644A2 (en) 2004-10-01 2006-04-13 Medarex, Inc. Methods of treating cd30 positive lymphomas
WO2006089232A2 (en) 2005-02-18 2006-08-24 Medarex, Inc. Monoclonal antibodies against cd30 lacking fucosyl residues

Also Published As

Publication number Publication date
CA2582016A1 (en) 2006-04-13
EP1802345A2 (en) 2007-07-04
KR20070083899A (ko) 2007-08-24
ZA200703154B (en) 2008-09-25
WO2006039644A3 (en) 2006-08-10
MX2007003533A (es) 2007-05-23
WO2006039644A2 (en) 2006-04-13
IL182260A0 (en) 2007-07-24
JP2008514730A (ja) 2008-05-08
US7790160B2 (en) 2010-09-07
BRPI0516727A (pt) 2008-09-16
AU2005292227A1 (en) 2006-04-13
CN101056655A (zh) 2007-10-17
US20060177442A1 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
NO20071714L (no) Fremgangsmateer for behandling av CD30 positive lymfomer
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
NO20070052L (no) Fremgangsmate for behandling av multippel sklerose
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
MY160041A (en) Compositions and methods for treating parasitic infections
EA200702048A1 (ru) Фармакокинетически улучшенные соединения
NO20170633A1 (no) Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff .
EA201300246A1 (ru) Ингибиторы тирозинкиназы брутона
NO20092658L (no) New compounds
DE602005014127D1 (de) Medizinische vorrichtung und herstellungsverfahren dafür
TW200714590A (en) Heterocyclic inhibitors of MEK and methods of use thereof
DE602005009748D1 (de) 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
NO20090157L (no) Tienpyrimidiner anvendelige som modulatorer av ionekanaler
EA200870185A1 (ru) Комбинации ингибиторов ang2 и vegf
MY169308A (en) Treatment of tnf? related disorders
EA201070247A1 (ru) Ингибиторы протеасом
LU92338I2 (fr) Enzalutamide et ses sels pharmaceutiquement acceptables (XTANDI)
TW200637574A (en) Treatment method
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
ATE350377T1 (de) Substituierte 3-pyrrolidin-indol-derivate
ATE527251T1 (de) Bicyclische derivate als modulatoren von ionenkanälen
ATE540036T1 (de) Heterocyclische derivate als ionenkanalmodulatoren
TW200716224A (en) Method of indentifying therapeutic targets for the treatment of vulvovaginal atrophy
TW200508233A (en) Chk-1 inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application